| HER2-low breast cancer: molecular characteristics and prognosis E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos, ... Cancers 13 (11), 2824, 2021 | 178 | 2021 |
| Characterizing CDK12-mutated prostate cancers P Rescigno, B Gurel, R Pereira, M Crespo, J Rekowski, M Rediti, ... Clinical Cancer Research 27 (2), 566-574, 2021 | 77 | 2021 |
| Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker … L Incorvaia, D Fanale, G Badalamenti, C Porta, D Olive, I De Luca, ... Oncoimmunology 9 (1), 1832348, 2020 | 71 | 2020 |
| Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients B Neri, A Vannini, M Brugia, A Muto, S Rangan, M Rediti, R Tassi, ... International journal of urology 20 (5), 478-483, 2013 | 59 | 2013 |
| Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges X Wang, L Collet, M Rediti, V Debien, A De Caluwé, D Venet, E Romano, ... Journal of clinical medicine 12 (3), 953, 2023 | 32 | 2023 |
| Early post-treatment prostate-specific antigen at 4 weeks and abiraterone and enzalutamide treatment for advanced prostate cancer: an international collaborative analysis P Rescigno, D Dolling, V Conteduca, M Rediti, D Bianchini, C Lolli, M Ong, ... European urology oncology 3 (2), 176-182, 2020 | 23 | 2020 |
| Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis F Rothé, D Venet, D Peeters, G Rouas, M Rediti, D Smeets, F Dupont, ... NPJ Breast Cancer 8 (1), 79, 2022 | 17 | 2022 |
| Timing evolution of lobular breast cancer through phylogenetic analysis D Fimereli, D Venet, M Rediti, B Boeckx, M Maetens, S Majjaj, G Rouas, ... EBioMedicine 82, 2022 | 10 | 2022 |
| Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report M Rediti, E Pellegrini, E Molinara, C Cerullo, C Fonte, A Lunghi, A Iori, ... Anticancer Research 34 (2), 905-907, 2014 | 10 | 2014 |
| Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials M Rediti, A Fernandez-Martinez, D Venet, F Rothé, KA Hoadley, ... Nature communications 14 (1), 7053, 2023 | 8 | 2023 |
| Copy number aberration analysis to predict response to neoadjuvant Anti-HER2 therapy: results from the NeoALTTO Phase III clinical trial D Venet, M Rediti, M Maetens, D Fumagalli, DN Brown, S Majjaj, ... Clinical Cancer Research 27 (20), 5607-5618, 2021 | 8 | 2021 |
| Fenor de la Maza MD P Rescigno, B Gurel, R Pereira, M Crespo, J Rekowski, M Rediti, ... Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I …, 2021 | 8 | 2021 |
| Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials A Fernandez-Martinez, M Rediti, G Tang, T Pascual, KA Hoadley, D Venet, ... JAMA oncology 10 (5), 603-611, 2024 | 6 | 2024 |
| Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy M Rediti, C Messina Breast Cancer Research and Treatment 172, 239-240, 2018 | 5 | 2018 |
| PI3K/AKT pathway deleterious mutations in lethal prostate cancer P Rescigno, M Rediti, D Dolling, DN Rodrigues, D Bianchini, R Riisnaes, ... Annals of Oncology 29, viii293, 2018 | 5 | 2018 |
| Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer. M Barrero, M Rediti, M Crespo, D Dolling, P Rescigno, C Messina, ... Journal of Clinical Oncology 36 (15_suppl), 5070-5070, 2018 | 5 | 2018 |
| The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases B Neri, A Vannini, R Tassi, M Brugia, S Rangan, M Rediti, C Cerullo Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 20 …, 2012 | 5 | 2012 |
| HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021; 13 (11): 2824 E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos | 5 | |
| Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: a pooled analysis of CALGB 40601, NeoALTTO … A Fernandez-Martinez, M Rediti, G Tang, T Pascual, KA Hoadley, D Venet, ... Journal of Clinical Oncology 40 (16_suppl), 509-509, 2022 | 4 | 2022 |
| HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021 E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos | 4 | |
